Ablynx NV, a biopharmaceutical company, engages in

Ablynx NV, a biopharmaceutical company, engages in the discovery and development of Nanobodies, a class of therapeutic proteins based on single-domain antibody fragments for various serious and life-threatening human diseases. The company develops products for various disease areas, including inflammation, haematology, oncology, and pulmonary diseases. Its lead programs include caplacizumab, an anti-vWF Nanobody that is in Phase II clinical trial to treat acquired thrombocytopenic purpura; ozoralizumab, subcutaneously administered, half-life extended Nanobody, which is in Phase IIb clinical trial for the treatment of rheumatoid arthritis; and ALX-0061, a half-life extended Nanobody that is in Phase I/II study for the treatment of rheumatoid arthritis. The company also develops ALX-0141, which has completed Phase I trials to treat bone related disorders, including osteoporosis and bone metastases; ALX-0171 that is under Phase I clinical trial for the treatment of respiratory syncytial virus infection in infants; ALX-0761, which is in pre-clinical stage for use in inflammation/immunology therapeutic areas; and ALX-0751 that is in pre-clinical stage for use in oncology therapeutic area. It has a strategic alliance with Boehringer Ingelheim to discover, develop, and commercialize various Nanobody programmes; license, development, and commercialization agreement with Novartis to discover Nanobodies for various targets; and co-discovery and co-development agreement with Merck Serono to research and develop Nanobody-based therapeutics for oncology, immunology, inflammatory disease, and osteoarthritis. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.